Indivior rose to 46th on the Top 100 Stocks to Buy list, gaining 11 spots. Technical Opinion: Strong Buy. Net profit in the first half of 2025 was $65 million, up 281% from a loss of $36 million in 2024. Revenue projection for 2025 is $1.055 billion.

Indivior, a UK-based pharma company, spun off from Reckitt Benckiser in 2015. Revenue estimates for 2025 are promising, with expectations to grow its U.S. Sublocade product. Settlement in 2020 led to a payment of $600 million and ongoing litigation expenses.

New CCO Pat Barry aims to accelerate growth in 2026. Indivior focuses on Sublocade revenue, with potential in the U.S. market. Analysts rate it a Buy. With operational income at record highs, the company looks poised for future success.

Litigation settlement expenses are reducing, strengthening the financial position. Analysts have a target price of $29.40 for Indivior stock. The company’s future success hinges on generating enough cash flow for product development beyond Sublocade.

Oaktree Capital Management’s activism led to a change in leadership, driving renewed growth and profitability. Indivior’s focus on Sublocade and financial discipline could lead to significant rewards. With a solid operating income, the company appears well-positioned for success.

Read more at Yahoo Finance: Indivior Advances Into Top 50 on Momentum